Clinical Trial: Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers
Study Status: Completed
Recruit Status: RECRUITING
Condition: Biliary Tract Carcinoma
Study Type: INTERVENTIONAL
Official Title: Study of Gemcitabine, Cisplatin, Quemliclustat (AB680) and Zimberelimab (AB122) During First Line Treatment of Advanced Biliary Tract Cancers (BTC).
Brief Summary:
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC).The study will include a safety run-in involving 6 study participants.The goal of the safety run-in is to screen for early safety signals of the proposed drug combination.Trial enrollment can continue while full safety assessment is being completed for the first 6 subjects.Participants will receive 4 cycles of combination therapy as described.After 4…
Read more